JP7071287B2 - 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 - Google Patents

繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 Download PDF

Info

Publication number
JP7071287B2
JP7071287B2 JP2018560460A JP2018560460A JP7071287B2 JP 7071287 B2 JP7071287 B2 JP 7071287B2 JP 2018560460 A JP2018560460 A JP 2018560460A JP 2018560460 A JP2018560460 A JP 2018560460A JP 7071287 B2 JP7071287 B2 JP 7071287B2
Authority
JP
Japan
Prior art keywords
fibromyalgia
general formula
pharmaceutical composition
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018560460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516707A5 (enExample
JP2019516707A (ja
Inventor
チョ・ミンジェ
イ・ハンジュ
ファン・ソングァン
Original Assignee
エスケー バイオファーマスティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスケー バイオファーマスティカルズ カンパニー リミテッド filed Critical エスケー バイオファーマスティカルズ カンパニー リミテッド
Publication of JP2019516707A publication Critical patent/JP2019516707A/ja
Publication of JP2019516707A5 publication Critical patent/JP2019516707A5/ja
Application granted granted Critical
Publication of JP7071287B2 publication Critical patent/JP7071287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2018560460A 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 Active JP7071287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516707A JP2019516707A (ja) 2019-06-20
JP2019516707A5 JP2019516707A5 (enExample) 2020-06-25
JP7071287B2 true JP7071287B2 (ja) 2022-05-18

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560460A Active JP7071287B2 (ja) 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用

Country Status (13)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EP3711757B1 (en) * 2017-11-14 2025-05-07 SK Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538557A (ja) 2005-04-22 2008-10-30 エスケー ホルディングス カンパニー リミテッド 神経治療アゾール化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
RU2299729C2 (ru) * 2001-07-16 2007-05-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
AU2009348523B2 (en) * 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538557A (ja) 2005-04-22 2008-10-30 エスケー ホルディングス カンパニー リミテッド 神経治療アゾール化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROLOGIC ASPECTS OF SYSTEMIC DISEASE PART I; "Chapter 33: Fibromyalgia"，HANDBOOK OF CLINICAL NEUROLOGY，Vol.119(3rd series)，2014年，p.513-527

Also Published As

Publication number Publication date
ES2935596T3 (es) 2023-03-08
PL3459543T3 (pl) 2023-04-11
EP3459543B1 (en) 2022-12-21
US20190298694A1 (en) 2019-10-03
MX394245B (es) 2025-03-19
BR112018073553A2 (pt) 2019-03-19
CN109475529A (zh) 2019-03-15
RU2018144785A (ru) 2020-06-19
EP3459543A4 (en) 2020-01-15
KR102489052B1 (ko) 2023-01-16
DK3459543T3 (da) 2023-02-13
CA3024286A1 (en) 2017-11-23
WO2017200318A1 (ko) 2017-11-23
MX2018014080A (es) 2019-04-04
US10849882B2 (en) 2020-12-01
RU2753525C2 (ru) 2021-08-17
CN109475529B (zh) 2022-02-22
RU2018144785A3 (enExample) 2020-08-11
AU2017265839B2 (en) 2022-10-27
AU2017265839A1 (en) 2018-12-13
KR20170131242A (ko) 2017-11-29
EP3459543A1 (en) 2019-03-27
JP2019516707A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
CN109475529B (zh) 氨基甲酸酯化合物用于预防或治疗纤维肌痛或与纤维肌痛相关的功能综合征的用途
US12611395B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
EP3711757B1 (en) Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
CA3024286C (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
AU2017374459A1 (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
BR112018073556B1 (pt) Uso de um composto de carbamato
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220506

R150 Certificate of patent or registration of utility model

Ref document number: 7071287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250